Arax Advisory Partners’s Humacyte HUMA Stock Holding History
Bought
Maintained
Sold
Other funds holding HUMA
Arax Advisory Partners's HUMA Position: Q3 2026 in Review
Arax Advisory Partners reduced its Humacyte (HUMA) stake by 82% in Q3 2026, selling an estimated $22K and leaving 7,535 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4756.
Arax Advisory Partners first reported a position in HUMA in Q2 2024 and has held it in 10 quarters since. The position peaked at $32.7K in Q2 2026. 130 funds tracked by Wall St. Rank hold HUMA as of Q3 2026.
- Arax Advisory Partners held 7,535 shares of Humacyte worth $3.9K as of Q3 2026.
- Arax Advisory Partners sold 34,364 Humacyte shares in Q3 2026, an estimated $22K.
- Humacyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4756 holding.
- Arax Advisory Partners first reported a position in Humacyte in Q2 2024 and has held it in 10 quarters since.
- Arax Advisory Partners's Humacyte position peaked at $32.7K in Q2 2026.
- 130 funds tracked by Wall St. Rank held Humacyte as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.